Broncho-Vaxom children's caps. 3.5 mg # 30

Release form

Hard gelatin capsules, size No. 3, blue opaque cap, white opaque body

the contents of the capsules are light beige powder.

Packaging

0 pcs.

- blisters (3) - cardboard packs.

pharmachologic effect

Immunostimulating drug of bacterial origin.

Broncho-Vaxom for children stimulates the body's immune defenses and increases resistance to infections of the respiratory system.

Immunopharmacological studies have shown that Broncho-Vaxom for children has the following effect: increases the formation of immunoglobulins A (IgA), secreted by the mucous membrane of the respiratory tract and saliva

increases the number of circulating T-lymphocytes.

Clinically, Broncho-Vaxom for children reduces the frequency of acute respiratory tract infections, shortens the duration of their course, and also reduces the likelihood of exacerbation of chronic bronchitis.

This reduces the need for the use of other drugs, especially antibiotics.

Pharmacokinetics.

Data on the pharmacokinetics of Broncho-Vaxom for children have not been provided.

Indications

Children aged 6 months to 12 years:

prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis

treatment of acute respiratory tract infections (as part of complex therapy).

Contraindications

Hypersensitivity to drug components.

special instructions

Based on the available data, it is not recommended to prescribe Broncho-Vaxom for children under 6 months of age due to the immaturity of their immune system.

To avoid overdose, do not use the drug from capsules intended for adults (Broncho-Vaxom adult capsules 7 mg).

Influence on the ability to drive vehicles and use mechanisms

Broncho-Vaxom for children does not affect the ability to drive vehicles and work with mechanisms.

Structure

1 caps.

standardized lyophilisate of bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis 3.5 mg

Excipients: anhydrous propyl gallate (E310) - 0.042 mg, monosodium glutamate (corresponds to anhydrous sodium glutamate (sodium glutamate)) - 1.515 mg, mannitol - the required amount up to 20 mg, pregelatinized starch - 110 mg, magnesium stearate - 3 mg, mannitol - the required amount is up to 200 mg.

The composition of the capsule shell: indigo carmine (indigotin) (dye E132) - 0.01 mg, titanium dioxide (dye E171) - 1 mg, gelatin - the required amount up to 50 mg.

Method of administration and dosage

Broncho-Vaxom for children is prescribed for children aged 6 months to 12 years.

For the purpose of treatment: 1 capsule of the drug Broncho-Vaxom for children daily in the morning on an empty stomach until the symptoms disappear, but not less than 10 days.

If antibiotic therapy is necessary, Broncho-Vaxom for children should be taken in combination with an antibiotic from the beginning of treatment.

The duration of treatment or the appointment of a repeated course of therapy should be determined by the doctor, based on the patient's state of health.

In order to prevent exacerbations and maintenance therapy: 1 capsule of Broncho-Vaxom for children daily in the morning on an empty stomach.

The course includes 3 cycles, each of which consists of taking 1 capsule daily for 10 days, the interval between cycles is 20 days.

If the capsule is difficult to swallow, open it and mix the contents with drink (including fruit juice, milk).

Side effects

Broncho-Vaxom for children is usually well tolerated.

The results of clinical studies indicate that the incidence of mild adverse reactions is 3-4%.

From the digestive system: nausea, abdominal pain, vomiting.

Dermatological reactions: itching, erythema.

From the respiratory system: cough, shortness of breath.

From the nervous system: headache

Name ENG

BRONCHO-VAXOM ADULTS

Clinical and pharmacological group

Immunostimulating drug of bacterial origin

ATX code

Other immunostimulants

Dosage

3.5mg

Structure

1 caps .: standardized lyophilisate of bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis 3.5 mg.

Excipients: anhydrous propyl gallate (E310) - 0.042 mg, monosodium glutamate (corresponds to anhydrous sodium glutamate (sodium glutamate)) - 1.515 mg, mannitol - the required amount up to 20 mg, pregelatinized starch - 110 mg, magnesium stearate - 3 mg, mannitol - required amount up to 200 mg

Indications

Adults and children aged 12 and over:

prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis

treatment of acute respiratory tract infections (as part of complex therapy).

Storage conditions and periods

At a temperature of 15-25 degrees.

Expiration date: 5 years

INN / Active ingredient

Bacterial lysates

Specifications

Category

Cough

Scope of the drug

Respiratory system

Release form

Capsules

Manufacturer country

Switzerland

Package quantity, pcs

thirty

Scope of application

Pulmonology

Minimum age from

12 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

OM Pharma CH

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Immunostimulating agent

Anatomical and therapeutic characteristics

L03AX Other immunostimulants

Dosage form

Capsules

Expiration date in days

1826

The target audience

Children

Package weight, g

25

Mode of application

:

Broncho-Vaxom for children is prescribed for children aged 6 months to 12 years. < br> For the purpose of treatment: 1 capsule of Broncho-Vaxom for children daily in the morning on an empty stomach until the symptoms disappear, but not less than 10 days. If antibiotic therapy is necessary, Broncho-Vaxom for children should be taken in combination with an antibiotic from the beginning of treatment. < br> The duration of treatment or the appointment of a repeated course of therapy should be determined by the doctor, based on the patient's state of health. < br> In order to prevent exacerbations and maintenance therapy: 1 capsule of Broncho-Vaxom for children daily in the morning on an empty stomach. The course includes 3 cycles, each of which consists of taking 1 capsule daily for 10 days, the interval between cycles is 20 days. If the capsule is difficult to swallow, open it and mix the contents with the drink (incl.with fruit juice, milk).

Dosage (volume) of the substance in the preparation

:

1 caps .: standardized lyophilisate of bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis 3.5 mg

Information on technical characteristics, delivery set, country of manufacture